List of Excipients in Branded Drug LACOSAMIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
VistaPharm Inc	LACOSAMIDE	lacosamide	66689-107	ACESULFAME POTASSIUM
VistaPharm Inc	LACOSAMIDE	lacosamide	66689-107	ANHYDROUS CITRIC ACID
VistaPharm Inc	LACOSAMIDE	lacosamide	66689-107	ASPARTAME

Generic Drugs Containing LACOSAMIDE

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	lacosamide	0121-0992	ACESULFAME POTASSIUM
PAI Holdings LLC dba PAI Pharma	lacosamide	0121-0992	ANHYDROUS CITRIC ACID
PAI Holdings LLC dba PAI Pharma	lacosamide	0121-0992	ASPARTAME

What are the Most Frequently-Used Excipients in LACOSAMIDE?

# Of NDCs	Excipient
6	ACESULFAME
17	ACESULFAME POTASSIUM
6	ACETIC ACID

Lacosamide Excipient Strategy and Commercial Opportunities

Last updated: September 30, 2026

Lacosamide is a mature antiseizure medicine with established tablet, oral-solution, and intravenous presentations. The commercial opportunity has shifted from molecule exclusivity to differentiated dosage forms, pediatric delivery, hospital supply reliability, excipient compatibility, and lower-cost generic manufacturing.

The strongest excipient strategies are low-risk immediate-release tablets, palatable oral liquids, preservative-controlled multidose solutions, and ready-to-use parenteral products. Because lacosamide is highly soluble enough for conventional oral and injectable products, complex enabling technologies are generally unnecessary.

What is lacosamide and which dosage forms are commercially established?

Lacosamide is a functionalized amino acid marketed originally as Vimpat by UCB. The FDA approved it in 2008 as adjunctive therapy for partial-onset seizures in adults. It later received approval for monotherapy and pediatric use, with oral tablets, oral solution, and injection products covering the principal administration routes.[1]

Product type	Typical strengths or concentration	Primary use	Excipient opportunity
Immediate-release tablet	50, 100, 150, 200 mg	Chronic outpatient therapy	Low-cost robust solid dosage form
Oral solution	10 mg/mL	Pediatric, geriatric, swallowing-impaired patients	Taste masking, preservative system, dosing-device differentiation
Intravenous injection	10 mg/mL	Hospital treatment and oral-to-IV substitution	Container closure, stability, ready-to-use supply
Generic equivalents	Same strengths and routes	Price-driven substitution	Manufacturing efficiency and supply reliability

Lacosamide is administered orally twice daily in most regimens. The molecule has a relatively predictable pharmacokinetic profile and does not require a modified-release platform for the core product. The commercial value of formulation work therefore depends on usability, stability, cost, and lifecycle positioning rather than on improving systemic exposure.[1]

What excipients are used in lacosamide tablets?

Lacosamide tablets use conventional immediate-release excipients. The U.S. Vimpat label identifies inactive ingredients that include microcrystalline cellulose, low-substituted hydroxypropyl cellulose, crospovidone, colloidal anhydrous silica, and magnesium stearate. The film coating contains hypromellose, titanium dioxide, talc, polyethylene glycol, and colorants that vary by strength.[1]

Core tablet excipient functions

Excipient class	Likely function in lacosamide tablets	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Widely available; supports direct compression
Low-substituted hydroxypropyl cellulose	Disintegrant or binder	Helps tablet breakup without complex processing
Crospovidone	Superdisintegrant	Supports immediate release
Colloidal silicon dioxide	Glidant and flow aid	Improves blend uniformity and tablet manufacture
Magnesium stearate	Lubricant	Controls ejection force; over-lubrication can affect dissolution
Hypromellose	Film-coating polymer	Protects tablet and supports identification
Polyethylene glycol	Coating plasticizer	Improves coating flexibility
Titanium dioxide and iron oxides	Opacifier and colorant	Enables strength differentiation and product recognition

A generic manufacturer can generally use a different excipient system if the product meets the relevant quality, bioequivalence, dissolution, and inactive-ingredient requirements. The primary technical risks are blend uniformity, tablet hardness, disintegration, dissolution, moisture control, and colorant compatibility.

What tablet formulation strategy offers the lowest cost?

A direct-compression formulation with microcrystalline cellulose, a superdisintegrant, silica, and magnesium stearate is usually the most commercially efficient approach. It reduces process steps compared with wet granulation and uses commodity excipients with multiple qualified suppliers.

Wet granulation may be justified where the selected lacosamide grade has poor flow, segregation risk, or inconsistent tablet compression. It normally adds manufacturing cost without creating a strong market advantage. For a commodity generic, the preferred formulation is likely a simple, scalable immediate-release tablet with a conventional film coat.

What excipients are used in lacosamide oral solution?

The U.S. oral solution contains lacosamide at 10 mg/mL. The labeled inactive ingredients include glycerin, sodium saccharin, sodium chloride, and flavoring, with pH adjustment using hydrochloric acid and sodium hydroxide.[1]

The oral solution creates the clearest excipient-led commercial opportunity because chronic antiseizure therapy includes children, older adults, patients with dysphagia, and patients transitioning from feeding tubes.

Key formulation requirements for oral liquid products

A competitive lacosamide oral solution should address:

1. Palatability after repeated dosing.
2. Chemical stability over the labeled shelf life.
3. Accurate dosing across oral syringes and cups.
4. Compatibility with enteral feeding tubes.
5. Low crystallization and precipitation risk.
6. Microbiological control in multidose packaging.
7. Minimal sorption to plastic containers and tubing.

Glycerin contributes sweetness, viscosity, and mouthfeel. Sodium saccharin provides high-intensity sweetness at low concentration. Flavor selection is commercially important because bitterness, aftertaste, and throat sensation can affect pediatric adherence.

A generic developer can pursue a differentiated flavor system, but flavor changes must remain compatible with the reference product’s safety and regulatory requirements. The commercial advantage is strongest where the product has improved acceptability without increasing sugar load, viscosity, osmolality, or dosing complexity.

What preservative strategy is appropriate?

The U.S. reference oral solution relies on its labeled formulation and packaging system for microbiological control. A generic product may use a comparable preservative approach or a preservative-free multidose design supported by validated packaging and in-use stability data.

Potential approaches include:

• A preservative-containing multidose bottle.
• A preservative-free bottle with a one-way dosing closure.
• Unit-dose oral-solution packaging.
• A pharmacy bulk package for institutional use.
• Amber bottles with oral syringes for light protection and dosing accuracy.

Preservative selection must account for pediatric exposure, flavor impact, pH, compatibility with elastomers, and regional regulatory requirements. Sodium benzoate, potassium sorbate, and parabens are common oral-liquid tools, but each can create pediatric, labeling, or palatability considerations. A low-preservative or preservative-free design can support premium positioning but may increase packaging and stability costs.

What excipients are used in lacosamide injection?

Vimpat injection is supplied at 10 mg/mL. The labeled formulation includes sodium chloride, hydrochloric acid for pH adjustment, and water for injection.[1]

The injection is a relatively simple aqueous parenteral product. Its main technical challenges are:

• Control of particulate matter.
• Container-closure integrity.
• pH and osmolality consistency.
• Sterility assurance.
• Compatibility with infusion containers and administration sets.
• Stability after dilution.
• Low extractables and leachables from packaging components.

The commercial opportunity is strongest in hospital-ready packaging. A manufacturer may differentiate through ready-to-dilute vials, premixed infusion bags, smaller institutional presentations, or improved labeling for oral-to-intravenous conversion. The product should not require a novel excipient or complex delivery system.

How does lacosamide compare with competing antiseizure drugs?

Lacosamide competes with levetiracetam, brivaracetam, lamotrigine, oxcarbazepine, carbamazepine, and other antiseizure medicines. Its formulation position differs by route and use case.

Drug	Common oral forms	IV form	Key formulation opportunity
Lacosamide	Tablet, oral solution	Yes	Pediatric liquid, hospital IV, supply reliability
Levetiracetam	Tablet, oral solution	Yes	High-volume generic efficiency and dosing flexibility
Brivaracetam	Tablet, oral solution	Yes	Premium branded lifecycle management
Lamotrigine	Tablet, chewable/dispersible	Limited or no routine IV product	Dispersible pediatric formats
Oxcarbazepine	Tablet, oral suspension	No standard IV substitute	Suspension palatability and dosing
Carbamazepine	Tablet, suspension	No routine IV use	Extended-release and suspension platforms

Levetiracetam is the principal high-volume generic benchmark. Lacosamide can command a higher unit value in settings where clinicians value its IV availability, oral-to-IV substitution, or use in patients who cannot take levetiracetam or other agents.

When did lacosamide lose U.S. exclusivity?

Lacosamide’s principal U.S. market protection has expired, and FDA-approved generic products are commercially available. The product’s exclusivity period originated from the 2008 approval of Vimpat, while later approvals expanded indications and pediatric coverage.[1,2]

What is the Orange Book status of lacosamide?

The FDA Orange Book identifies reference-listed drug information, patent listings, exclusivity, and approved dosage forms. Lacosamide’s current commercial landscape is primarily generic rather than originator-protected. The relevant market-entry issues are therefore abbreviated new drug application approval, bioequivalence, product-specific labeling, manufacturing compliance, and supply economics.[2]

Historically, UCB pursued patent protection covering lacosamide and methods of treating epilepsy. Those rights delayed or shaped generic entry through Paragraph IV litigation and settlement arrangements. The practical effect of the expired protection is that current competition focuses less on basic composition claims and more on formulation execution, manufacturing scale, and customer access.

Which companies are challenging lacosamide patents?

Generic manufacturers, including large U.S. and international generic companies, pursued abbreviated new drug applications for lacosamide tablets, oral solution, and injection after the relevant exclusivity barriers declined. Public FDA approval records identify multiple generic approvals across these dosage forms.[3]

The generic challenge has not created a meaningful biosimilar issue. Lacosamide is a small-molecule drug, not a biologic. The relevant regulatory pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under section 351(k).

What patent litigation and settlements affected lacosamide?

Lacosamide’s historical patent disputes centered on UCB’s listed patents and generic Paragraph IV certifications. Generic applicants could certify that listed patents were invalid, unenforceable, or would not be infringed. A Paragraph IV certification could trigger a patent-infringement action and an automatic stay of FDA approval for up to 30 months under applicable law.[4]

The commercial significance of those disputes was timing. Once the relevant protections expired, litigation ceased to be the primary barrier to entry. No active litigation is required for a generic manufacturer to face meaningful commercial risk. Pricing pressure, manufacturing interruptions, recall exposure, and limited hospital contracting can be more important than residual patent risk.

What formulation patents protect lacosamide products?

The strongest historical protection was associated with the active ingredient and therapeutic use rather than a highly complex delivery platform. Formulation patents, where listed or asserted, would have had narrower relevance than composition or method-of-use claims.

Potential formulation claim areas include:

• Specific oral-solution concentration and pH ranges.
• Taste-masked liquid formulations.
• Stable injectable solutions.
• Container-closure combinations.
• Dosing regimens linked to particular patient populations.
• Crystalline, polymorphic, or process-defined forms.
• Manufacturing processes that control impurities or particle attributes.

For a new entrant, freedom-to-operate analysis should distinguish expired core patents from any later patents covering liquid formulations, packaging, manufacturing processes, or specific therapeutic uses. Patent risk cannot be assessed solely by reviewing the original Vimpat composition patent.

How strong is the current lacosamide patent estate?

The current estate is commercially weaker than during the branded exclusivity period because the core molecule is genericized and multiple dosage forms are approved. Residual value may remain in narrow formulation, process, packaging, or method-of-use claims, but those claims are less likely to support broad market exclusivity.

Patent-estate category	Current commercial strength
Core molecule	Low after generic entry
Immediate-release tablets	Low to moderate, depending on claim scope
Oral solution	Moderate opportunity for narrow formulation claims
IV product	Moderate technical barrier, limited patent leverage
Manufacturing process	Moderate where impurity control is difficult
Pediatric method of use	Limited after exclusivity expiration
Packaging and device	Low to moderate, mainly lifecycle protection

The strongest defensible position for a new product is likely to combine formulation know-how, proprietary packaging, validated stability, and differentiated clinical usability rather than rely on a broad composition patent.

What commercial opportunities exist for lacosamide excipients?

Pediatric and dysphagia-focused oral solution

A better-tasting 10 mg/mL oral solution can target pediatric neurology, long-term-care facilities, and patients unable to swallow tablets. The most valuable improvements are practical: reduced bitterness, easy dose measurement, low viscosity, and compatibility with feeding tubes.

Unit-dose and adherence packaging

Single-use oral-solution sachets, oral syringes, and calendarized packaging can reduce dosing errors. These formats are particularly relevant to specialty pharmacies, hospitals, and institutional care.

Hospital IV supply

Generic lacosamide injection can compete through reliable availability, flexible vial sizes, premixed presentations, and reduced preparation steps. Hospital buyers often value dependable supply more than minor excipient differences.

Global-market reformulation

Excipient restrictions vary by jurisdiction. A supplier can develop region-specific versions that avoid colorants, high-sugar systems, certain preservatives, or animal-derived excipients. Excipients with broad global acceptability can simplify regulatory filings and supply chains.

Clean-label positioning

A tablet or oral liquid using fewer colorants, lower preservative content, or broadly recognized excipients may appeal to selected caregivers and institutional buyers. This is a positioning opportunity, not a substitute for bioequivalence and stability performance.

What generic launch risks exist for lacosamide?

The principal risks are commercial and operational:

• Rapid price erosion after multiple ANDA approvals.
• Low margins for common tablet strengths.
• Hospital tender concentration for injection.
• FDA manufacturing observations or supply interruptions.
• Oral-solution stability failures.
• Pediatric palatability shortcomings.
• Packaging changes that trigger regulatory supplements.
• Limited differentiation among generic tablets.
• Competition from levetiracetam and brivaracetam.
• Channel inventory compression after additional entrants.

A tablet-only launch faces the greatest commoditization risk. A portfolio covering tablets, oral solution, and injection has better contracting leverage and can reduce dependence on one dosage form.

How should a company prioritize lacosamide development?

A practical sequence is:

1. Launch immediate-release tablets using a low-cost, conventional excipient platform.
2. Add oral solution with validated flavor, dosing-device, and enteral-tube performance.
3. Develop injection only if sterile manufacturing capacity and hospital contracting are available.
4. Use differentiated packaging to protect customer relationships.
5. Evaluate regional excipient restrictions before finalizing the master formulation.
6. Build dual-source supply for critical excipients and packaging components.
7. Protect formulation, packaging, and process improvements with targeted patents and trade secrets.

The commercial case is strongest for companies that already manufacture generic antiseizure medicines, have pediatric liquid capabilities, or can access hospital channels. A stand-alone tablet launch without cost leadership or distribution access is less attractive.

Key Takeaways

• Lacosamide is a genericized small-molecule antiseizure drug with established tablet, oral-solution, and IV formats.
• Conventional excipients are sufficient for the core products.
• Oral solution offers the clearest formulation differentiation through taste, preservative control, dosing accuracy, and tube compatibility.
• IV opportunity depends on hospital supply reliability, packaging, and ready-to-use presentation.
• The current patent estate is materially weaker than during Vimpat’s exclusivity period.
• Lacosamide has no biosimilar pathway because it is a small molecule.
• Generic competition makes tablet pricing highly sensitive to entrant count.
• A multi-dosage-form portfolio has stronger commercial prospects than a tablet-only strategy.
• Manufacturing reliability and excipient supply security may create more value than narrow residual patent claims.

FAQs About Lacosamide Excipient Strategy

What is the best sweetener for lacosamide oral solution?

Sodium saccharin is used in the U.S. reference oral solution, with glycerin contributing sweetness and mouthfeel. Alternative systems require evaluation for taste, stability, pediatric acceptability, and regulatory compatibility.

Does lacosamide require a modified-release formulation?

No. The established product is immediate release, and conventional twice-daily dosing does not inherently require an extended-release platform.

Can lacosamide oral solution be preservative-free?

Yes, a preservative-free design may be possible with suitable packaging, microbiological controls, and in-use stability data. The commercial tradeoff is higher packaging and validation cost.

Is lacosamide a biologic subject to biosimilar competition?

No. Lacosamide is a chemically synthesized small molecule. Competition proceeds through generic drug applications, primarily ANDAs.

Which lacosamide dosage form has the greatest commercial potential?

The oral solution has the strongest excipient-led differentiation potential. Tablets offer the lowest manufacturing cost but face the most intense price competition. Injection can be attractive where a manufacturer has hospital distribution and sterile-product capacity.

References

1. U.S. Food and Drug Administration. (2023). Vimpat (lacosamide) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database, lacosamide products. FDA.

4. U.S. Food and Drug Administration. (2024). Generic drug user fees and abbreviated new drug applications. FDA.

5. UCB. (2024). Annual report 2023. UCB S.A.